Bioventus Inc. ( BVS ) NASDAQ Global Select

Cena: 6.74 ( 3.45% )

Aktualizacja 06-24 20:26
NASDAQ Global Select
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 1 030
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 57%
Ilość akcji: 62 965 800
Debiut giełdowy: 2021-02-11
WWW: https://www.bioventus.com
CEO: Mr. Robert E. Claypoole
Adres: 4721 Emperor Boulevard
Siedziba: 27703 Durham
ISIN: US09075A1088
Opis firmy:

Bioventus Inc. Firma urządzeń medycznych koncentruje się na rozwijaniu i komercjalizacji zabiegów klinicznych, które angażują i poprawiają naturalny proces gojenia organizmu w Stanach Zjednoczonych i na arenie międzynarodowej. Portfolio produktów firmy obejmuje leczenie bólu, które obejmują niechirurgiczne terapie wtrysku bólu stawów, a także produkty stymulacji nerwów obwodowych. Jego roztwory chirurgiczne obejmują substytuty przeszczepu kości w celu bezpiecznika i uprawy kości, zwiększają wyniki po operacji kręgosłupa i innych operacji ortopedycznych; oraz ultradźwiękowe urządzenia medyczne do stosowania w precyzyjnym rzeźbieniu kości, usuwania guzów i oczyszczania tkanek. Terapie naprawcze firmy obejmują ultradźwiękowy system gojenia kości do opieki nad złamaniami; przeszczepy skóry; oraz produkty, które są używane do wspierania gojenia się przewlekłych ran, a także zaawansowane urządzenia rehabilitacyjne zaprojektowane w celu pomocy pacjentom w odzyskaniu funkcji nogi lub ręki. Służy lekarzom obejmującym kontinuum ortopedyczne, w tym medycynę sportową, całkowitą rekonstrukcję stawów, kończyny dłoni i górnych, stóp i kostkę, chirurgię podiatryczną, uraz, kręgosłup i neurochirurgia w biurze lub klinice lekarza, ambulatoryjnych ośrodkach chirurgicznych lub w szpitalu. Firma została założona w 2011 roku i ma siedzibę w Durham w Karolinie Północnej.

Wskaźniki finansowe
Kapitalizacja (USD) 447 582 012
Aktywa: 769 492 000
Cena: 6.74
Wskaźnik Altman Z-Score: 0.9
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -14.1
Ilość akcji w obrocie: 57%
Średni wolumen: 394 685
Ilość akcji 66 357 600
Wskaźniki finansowe
Przychody TTM 555 061 000
Zobowiązania: 582 659 000
Przedział 52 tyg.: 5.28 - 14.38
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -0.5
P/E branży: 26.8
Beta: 0.88
Raport okresowy: 2025-08-04
WWW: https://www.bioventus.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Mark L. Singleton Senior Vice President & Chief Financial Officer 740 045 1970
Mr. Anthony D'Adamio Senior Vice President, General Counsel & Corporate Secretary 705 375 1961
Ms. Katrina J. Church J.D. Senior Vice President & Chief Compliance Officer 0 1962
Mr. Mike Crowe B.S., M.B.A. Senior Vice President of Operations 0 0
Mr. Robert E. Claypoole President, Chief Executive Officer & Director 0 1972
Ms. Helen Leupold Senior Vice President & Chief Human Resources Officer 0 0
Mr. David Crawford Vice President of Investor Relations & Treasurer 0 0
Mr. Larry Chen Managing Director of China & Asia Pacific 0 0
Wiadomości dla Bioventus Inc.
Tytuł Treść Źródło Aktualizacja Link
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com 2025-05-06 20:55:23 Czytaj oryginał (ang.)
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago. zacks.com 2025-05-06 13:45:39 Czytaj oryginał (ang.)
Bioventus Reports First Quarter Financial Results DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025. globenewswire.com 2025-05-06 11:30:00 Czytaj oryginał (ang.)
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025 DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. globenewswire.com 2025-04-28 12:00:00 Czytaj oryginał (ang.)
4 Healthcare Stocks to Buy as the Sector Faces Government Heat Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies. zacks.com 2025-04-17 13:25:38 Czytaj oryginał (ang.)
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com 2025-03-31 14:55:35 Czytaj oryginał (ang.)
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-03-17 15:00:21 Czytaj oryginał (ang.)
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. seekingalpha.com 2025-03-11 16:31:04 Czytaj oryginał (ang.)
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents. benzinga.com 2025-03-11 13:17:40 Czytaj oryginał (ang.)
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. zacks.com 2025-03-11 11:46:11 Czytaj oryginał (ang.)
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial guidance for full-year 2025. globenewswire.com 2025-03-11 09:30:00 Czytaj oryginał (ang.)
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. globenewswire.com 2025-02-28 09:30:00 Czytaj oryginał (ang.)
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture. zacks.com 2025-01-03 14:00:37 Czytaj oryginał (ang.)
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company's core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity. globenewswire.com 2025-01-02 10:00:00 Czytaj oryginał (ang.)
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. zacks.com 2024-12-23 12:40:32 Czytaj oryginał (ang.)
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-12-06 12:55:30 Czytaj oryginał (ang.)
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call. seekingalpha.com 2024-11-05 14:26:31 Czytaj oryginał (ang.)
Bioventus (BVS) Matches Q3 Earnings Estimates Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. zacks.com 2024-11-05 11:45:36 Czytaj oryginał (ang.)
Bioventus Reports Third Quarter Financial Results DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. globenewswire.com 2024-11-05 09:30:00 Czytaj oryginał (ang.)
Are Medical Stocks Lagging Bioventus (BVS) This Year? Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year. zacks.com 2024-11-04 12:45:48 Czytaj oryginał (ang.)
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings? Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results. zacks.com 2024-10-29 12:35:31 Czytaj oryginał (ang.)
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. globenewswire.com 2024-10-29 09:30:00 Czytaj oryginał (ang.)
Bioventus Surges 73% in Three Months: Time to Buy the Stock? BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises. zacks.com 2024-10-22 14:35:23 Czytaj oryginał (ang.)
First September Gains in 5 Years? Buy 3 Breakout Stocks Now Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today. zacks.com 2024-09-23 20:06:21 Czytaj oryginał (ang.)
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy? BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises. zacks.com 2024-09-19 17:50:19 Czytaj oryginał (ang.)
Bull Of The Day: Bioventus (BVS) This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion. zacks.com 2024-08-29 12:10:32 Czytaj oryginał (ang.)
Executives Buying W. P. Carey And 2 Other Stocks Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. benzinga.com 2024-08-21 11:37:29 Czytaj oryginał (ang.)
5 Small Drug Stocks to Buy as Innovation Reaches Peak Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio. zacks.com 2024-08-16 13:20:29 Czytaj oryginał (ang.)
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024 Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. seekingalpha.com 2024-08-12 15:01:47 Czytaj oryginał (ang.)
Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript Bioventus Inc. (NASDAQ:BVS ) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. seekingalpha.com 2024-08-11 17:45:25 Czytaj oryginał (ang.)
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. globenewswire.com 2024-08-07 20:15:00 Czytaj oryginał (ang.)
Bioventus Reports Second Quarter Financial Results DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 29, 2024. globenewswire.com 2024-08-06 11:30:00 Czytaj oryginał (ang.)